Beta Bionics initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst David Roman initiated coverage of Beta Bionics (BBNX) with a Neutral rating and $16 price target as part of a broader research note launching coverage on Diabetes Medical Technology. Diabetes technology is poised to sustain double-digit growth, and Beta Bionics technology is well suited for a targeted segment of the Type 1 market, the analyst tells investors in a research note. Goldman Sachs added however that while the company's near-term growth should outpace Diabetes peers and SMID cap MedTech, consensus estimates seem to largely capture the opportunity over the next several years, with valuation reflecting both that level of growth and the need to raise capital down the road to achieve cash flow breakeven.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Traders Load Up on Hedges Against Dramatic Fed Rate Cut Shifts
Traders are ramping up bets that hedge against dramatic shifts in the Federal Reserve's interest-rate path as questions on the economic impact of Trump's administration evolving policies persist. Overall, the swaps market continues to price in two rate reductions this year beginning in October. However, the uncertainty surrounding the outlook for the US economy has pushed traders in the options market to buy protection for a wider range of outcomes, from the possibility of no rate cuts at all, to a series of half-point reductions before the end of 2025. Goldman Sachs and Citigroup have also taken opposing views on when the Fed will start easing.
Business Wire
an hour ago
- Business Wire
Cerus Corporation to Participate in the Goldman Sachs 46 th Annual Global Healthcare Conference 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the management team are scheduled to present at the Goldman Sachs 46 th Annual Global Healthcare Conference 2025 in Miami, Florida, on Wednesday, June 11, 2025, at 8:40 a.m. Eastern Time. A live webcast of the presentation can be accessed via the Events & Presentation section of Cerus' Investor Relations website at A replay of the webcast will be available on Cerus Investor Relations website shortly after the event for 30 days. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Business Insider
2 hours ago
- Business Insider
One chart shows why nervous stock investors should feel OK about climbing bond yields
Bond market volatility has made investors nervous, but stocks can still thrive amid high yields. Goldman analysts say there is little correlation between bond yields and median S&P 500 returns. Still, higher yields could constrain stocks for the time being, the bank wrote. The bond market's recent freakout over tariffs and the deficit has received a lot of attention from nervous stock investors, but one chart shows the S&P 500 can keep climbing higher in 2025, according to Goldman Sachs. Analysts at the investment bank pointed to investor concern swirling around the US bond market, with Treasury yields spiking in recent weeks as traders fretted over the US's yawning budget deficit and the impact of tariffs on the economy. Those worries sent the 10-year US Treasury yield — a reflection of long-term interest rate expectations in the economy — past 4.5% in late May. The 10-year yield has since pulled back slightly to trade around 4.4%. But historically, the 10-year US Treasury yield hasn't had all that much of an impact on annual S&P 500 returns, the bank said. Since 1940, when the 10-year yield hovered between 4% and 5%, the benchmark index saw a median gain of 11%. But stocks have gained more in years when the yield was both higher and lower, analysts said, concluding there was no clear relationship between bond yields and stock market returns. "We believe that the drivers and speed of changes in bond yields matter more for equities than a specific level of rates," analysts wrote in a client note last week. Goldman still thinks that bond yields at current levels near 4.5% should "constrain the magnitude" of how much the S&P 500's valuation can grow. Historically, stocks have struggled to move higher once bond yields rise more than two standard deviations in a single month, which would be equivalent to the 10-year US Treasury yield spiking to 4.9% from its current levels, the analysts said. Still, the bank expects the 10-year yield to hover around its current levels for the rest of 2025, pointing to expectations that the economy will still see "below-trend" growth and "above-target" inflation. Lower growth can influence the Fed to cut interest rates to boost the economy, but higher prices influence the central bank to keep rates steady to control inflation, leaving monetary policy at a standstill. The S&P 500 also looks like it's trading close to fair value from a price-to-earnings perspective, Goldman said, suggesting the index could remain relatively flat for some time. Still, investors have been wary of wild swings in the bond market lately, with some commentators speculating that bond vigilantes — traders who stage a sell-off in bonds to protest government policies — may be influencing yields higher. Historically, these swings are unusual, and could be a sign that investors are growing more wary about purchasing US debt securities as a safe haven, investing experts told BI.
